| Market Cap | 1.58B | P/E | - | EPS this Y | -200.00% | Ern Qtrly Grth | - |
| Income | 12.67M | Forward P/E | -211.00 | EPS next Y | 688.90% | 50D Avg Chg | -56.00% |
| Sales | 233.66M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -38.00% |
| Dividend | N/A | Price/Book | 53.28 | EPS next 5Y | - | 52W High Chg | -70.00% |
| Recommedations | 2.10 | Quick Ratio | 5.00 | Shares Outstanding | 154.42M | 52W Low Chg | 117.00% |
| Insider Own | 9.08% | ROA | 4.93% | Shares Float | 135.51M | Beta | 2.32 |
| Inst Own | 59.28% | ROE | 11.57% | Shares Shorted/Prior | 35.71M/34.19M | Price | 10.55 |
| Gross Margin | 93.95% | Profit Margin | 5.42% | Avg. Volume | 4,329,672 | Target Price | 30.43 |
| Oper. Margin | -28.39% | Earnings Date | Apr 29 | Volume | 12,845,372 | Change | 0.57% |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
| HC Wainwright & Co. | Buy | Apr 18, 24 |
| JP Morgan | Overweight | Apr 18, 24 |
| Ladenburg Thalmann | Buy | Apr 18, 24 |
| HC Wainwright & Co. | Buy | Mar 1, 24 |
| Goldman Sachs | Neutral | Feb 29, 24 |
| HC Wainwright & Co. | Buy | Feb 28, 24 |
| B. Riley Securities | Buy | Feb 5, 24 |
| HC Wainwright & Co. | Buy | Jan 11, 24 |
| JP Morgan | Overweight | Nov 1, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Charney Laurence N | Director Director | Jan 05 | Sell | 19.03 | 17,500 | 333,025 | 237,229 | 01/08/24 |
| Power Sean A | CFO CFO | Jan 03 | Sell | 16.91 | 47,867 | 809,431 | 606,969 | 01/05/24 |
| WEISS MICHAEL S | CEO and President CEO and President | Aug 11 | Buy | 10.13 | 100,000 | 1,013,000 | 12,073,021 | 08/14/23 |
| Lonial Sagar | Director Director | Jun 23 | Sell | 23.370 | 34,854 | 814,538 | 93,878 | 06/26/23 |
| Power Sean A | Chief Financial Offi.. Chief Financial Officer | Jun 02 | Sell | 26.70 | 73,647 | 1,966,375 | 654,836 | 06/05/23 |
| Echelard Yann | Director Director | Jan 06 | Buy | 10.64 | 9,000 | 95,760 | 201,848 | 01/06/23 |
| Charney Laurence N | Director Director | Jan 04 | Sell | 11.10 | 30,000 | 333,000 | 234,729 | 01/06/23 |
| Power Sean A | CFO, Secretary and T.. CFO, Secretary and Treasurer | Jan 04 | Sell | 18.76 | 84,965 | 1,593,943 | 568,483 | 01/07/22 |
| WEISS MICHAEL S | CEO and President CEO and President | Dec 29 | Sell | 18.76 | 68,220 | 1,279,807 | 10,988,021 | 01/07/22 |